Plum SEC
  • Korean Stock
  • Company Information
  • Customer Service

Korean Stock

AI 공시
EXCH
Daewoong Pharma
★★
Completion of Licensor Succession for mRNA-based ERA Platform Technology Transfer Agreement (Total USD 239M)
 18h ago
PERI
Daewoong Pharma
★
Daewoong Pharmaceutical 2026 Q1: Revenue Growth Continues, Operating Profit Declines, New Technology Acquisition and Pipeline Strength
 05/15/2026, 03:46 PM
EXCH
Daewoong Pharma
★★
Technology Introduction Contract Signed for INV-008 (15-PGDH Inhibitor)
 05/12/2026, 05:40 PM
EXCH
Daewoong Pharma
★★
Q1 2026 Preliminary Results: Operating Profit Down, Net Income Up
 05/12/2026, 03:48 PM
EXCH
Daewoong Pharma
★★
Assumption of Licensor Position in mRNA-based ERA Technology (Contract with HanAll BioPharma)
 05/07/2026, 04:55 PM
EXCH
Daewoong Pharma
★★★★
Fexuclue Gets Additional Indication for H. pylori Eradication
 05/03/2026, 07:00 AM
  • «
  • 1
  • »
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.15